NO930679L - Tetrahydrotiofenderivater - Google Patents

Tetrahydrotiofenderivater

Info

Publication number
NO930679L
NO930679L NO93930679A NO930679A NO930679L NO 930679 L NO930679 L NO 930679L NO 93930679 A NO93930679 A NO 93930679A NO 930679 A NO930679 A NO 930679A NO 930679 L NO930679 L NO 930679L
Authority
NO
Norway
Prior art keywords
residue
hydrogen
pharmaceutically acceptable
formula
acceptable salts
Prior art date
Application number
NO93930679A
Other languages
English (en)
Other versions
NO930679D0 (no
Inventor
Shiro Mita
Yoichi Kawashima
Nobuharu Kato
Hiroshi Suhara
Koji Yoneda
Masataka Morishita
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of NO930679D0 publication Critical patent/NO930679D0/no
Publication of NO930679L publication Critical patent/NO930679L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • Control Of Electric Motors In General (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forbindelse med formel (I) og farmasøytisk akseptable salter derav; og et syntetisk mellomprodukt representer mved formel (II) og farmasøytisk akseptable salter derav, (I) (II) hvor R1 er hydrogen eller lavere alkyl; R2 er hydrogen eller en beskyttende gruppe for tiol: R3 er hydroksy, en rest av estergruppe eller en rest av amidogruppe; A er en rett eller forgrenet lavere alkylen, og svovelatomet i sidekjeden kan være direkte forbundet med -CO-til dannelse av en tiolaktonring. Forbindelsene har utmerkede thymulinlignende aktivi- teter og forventes å være nyttige for behandling av forskjellige immunforstyrrelser slik som immunosvikt- og autoimmunsykdommer.
NO93930679A 1992-02-28 1993-02-25 Tetrahydrotiofenderivater NO930679L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7924992 1992-02-28

Publications (2)

Publication Number Publication Date
NO930679D0 NO930679D0 (no) 1993-02-25
NO930679L true NO930679L (no) 1993-08-30

Family

ID=13684588

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930679A NO930679L (no) 1992-02-28 1993-02-25 Tetrahydrotiofenderivater

Country Status (12)

Country Link
US (1) US5292767A (no)
EP (1) EP0558287B1 (no)
JP (1) JP2818919B2 (no)
KR (1) KR930017877A (no)
CN (1) CN1035876C (no)
AT (1) ATE145902T1 (no)
AU (1) AU648217B2 (no)
CA (1) CA2090548A1 (no)
DE (1) DE69306278T2 (no)
FI (1) FI930873A (no)
NO (1) NO930679L (no)
TW (1) TW222629B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772783A (zh) * 2007-01-25 2012-11-14 中国生化制药工业协会 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012129A1 (en) * 1991-01-10 1992-07-23 Santen Pharmaceutical Co., Ltd. Cyclic compound
US5776859A (en) * 1995-11-15 1998-07-07 Nickel; Alfred A. Sodium channel active novel compounds and related processes and bioassay techniques
CN106831513A (zh) * 2017-01-06 2017-06-13 绍兴市上虞区耕创化工技术服务部 硫代乙酸钾的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012129A1 (en) * 1991-01-10 1992-07-23 Santen Pharmaceutical Co., Ltd. Cyclic compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772783A (zh) * 2007-01-25 2012-11-14 中国生化制药工业协会 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途

Also Published As

Publication number Publication date
CA2090548A1 (en) 1993-08-29
ATE145902T1 (de) 1996-12-15
DE69306278T2 (de) 1997-04-17
NO930679D0 (no) 1993-02-25
JP2818919B2 (ja) 1998-10-30
AU648217B2 (en) 1994-04-14
DE69306278D1 (de) 1997-01-16
FI930873A (fi) 1993-08-29
CN1079739A (zh) 1993-12-22
KR930017877A (ko) 1993-09-20
EP0558287A1 (en) 1993-09-01
AU3386093A (en) 1993-09-02
JPH05301867A (ja) 1993-11-16
EP0558287B1 (en) 1996-12-04
FI930873A0 (fi) 1993-02-26
CN1035876C (zh) 1997-09-17
TW222629B (no) 1994-04-21
US5292767A (en) 1994-03-08

Similar Documents

Publication Publication Date Title
LU91519I2 (fr) "Doripenem et ses dérivés pharmaceutiquement acceptables - DORIBAXr"
HUT70159A (en) Oxazolidinedion derivatives, pharmaceutical compositions containing them, their production and use
DE3176029D1 (en) Substituted acyl derivatives of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid
DE69330949D1 (de) Gaba und l-glutaminsaüre analoga zur behandlung der epilepsie
AU557691B2 (en) 2-penem antibiotics and their oxa-aza-, and carba analogues
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
FI934626A (fi) Substituerade bensylaminokinuklidiner
ES8605511A1 (es) Un procedimiento para la preparacion de derivados de tiazol,2, 4, disustituidos.
DE69313427D1 (de) Hexahydronapththalinesterderivate, ihre Herstellung und ihre therapeutischen Verwendungen
IE872588L (en) Compounds
ES8505352A1 (es) Procedimiento para la obtencion de nuevos derivados de mercaptoimidazol
ATE34394T1 (de) Therapeutisch aktive di-, tri-, tetra- und penta- aza-indene.
SE8802402D0 (sv) Novel esters
NO930679L (no) Tetrahydrotiofenderivater
TW225989B (no)
BG60248B1 (bg) Метод за получаване на производни на феноксиетиламина
ES2121058T3 (es) Compuestos antibioticos de carbapenem.
ATE139764T1 (de) Substituierte benzoate-derivate
ATE186907T1 (de) Optisch aktives 1-phenylpyrrolidonderivat und dessen herstellung
MY101827A (en) 2-[n-substitutedguanidino]-4-heteroarylthiazole antiulcer agents
MX9706187A (es) Derivados de 3-pirrolidiliden-2-ona-cefalosporinas.